People’s lives must come before profit

The poorest countries are missing out on adequate doses of vaccines – and the health implications should concern us all.

Nine months ago world leaders were queueing up to declare any Covid-19 vaccine a global public good. Today we are witness to a vaccine apartheid that is only serving the interests of powerful and profitable pharmaceutical corporations while costing us the quickest and least harmful route out of this crisis.

South Africa, a country whose HIV history should have taught us all the most appalling life-costing consequences of allowing pharmaceutical corporations to protect their medicine monopolies, has had to pay more than double the price paid by the European Union for the AstraZeneca vaccine for far fewer doses than it actually needs.

 Like so many other low- and middle-income countries, South Africa is today facing a vaccine landscape of depleted supply where it is purchasing power, not suffering, that will secure the few remaining doses.

Nine out of 10 people living in the poorest countries are poised to miss out on a vaccine this year. Production delays put even this figure in doubt. Unjustifiably high prices block access and threaten to push more countries into an ever-deeper debt crisis. If we continue to pursue the vaccine model we have, we will fail to get this pandemic under control for years to come.

Failure to change course will come at the cost of millions of lives and livelihoods around the world; to our progress on tackling poverty; to businesses, including those represented here at the World Economic Forum this week; and to our collective public health and economic security. Make no mistake, the costs of vaccine inequality will not be confined to those living in the poorest countries.

The longer the virus is allowed to continue in a context of patchy immunity, the greater the chance of mutations that could render the vaccines we have and the vaccines some people in rich countries have already received, less effective or ineffective.

Research commissioned by the International Chamber of Commerce published this week predicts that delays to vaccine access in poorer nations will also cost the global economy an estimated $9tn (£6.6tn), with nearly half of this absorbed in wealthy countries such as the US, Canada, Germany and the UK.

To clear the pathway for this, governments must also urgently back the proposal tabled to the World Trade Organization to temporarily waive intellectual property rights for Covid-19 vaccines, treatments and tests until the world has reached critically needed herd immunity and this pandemic is under control.

Source: article by Winnie Byanyima, an executive director of UNAids and a UN undersecretary general